问答:AI在药物开发中出错时谁来担责?——赛诺菲、Open Biopharma与GxP Frame专家谈AI对药物成功率、人工监督与数据治理的影响
Q&A: Who Is Accountable When AI Gets Drug Development Wrong?
BioPharm International与赛诺菲的Matt Truppo、Open Biopharma的Richard Jaenisch及GxP Frame的Brian Drapeau讨论AI在药物开发与生产中的问责问题。专家审视AI是否能可测量地提高治疗成功率,以及企业如何在AI工作中保持人工判断与数据治理的核心地位。讨论还涉及未来5至10年进入该领域专业人士应有何预期。
Commentary|Events|November 11, 2026
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
As AI becomes routine in drug development and manufacturing, attention is shifting from what the technology can do to what it can be trusted to do. In this second half of a discussion between BioPharm International® and Sanofi’s Matt Truppo, Open Biopharma’s Richard Jaenisch, and GxP Frame’s Brian Drapeau, the experts examine whether AI measurably improves the odds of therapeutic success, how companies keep human judgment and data governance at the center of AI-enabled work, and what success will look like in the near term. They also note what professionals entering the field should expect over the next 5 to 10 years.
Related to this article
November 10th, 2026
This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
November 6th, 2026
Johnson & Johnson's amivantamab (Rybrevant Faspro) won accelerated FDA approval for pretreated recurrent head and neck cancer.
November 5th, 2026
Akeso won NMPA priority review for ivonescimab plus chemotherapy in first-line biliary tract cancer after a phase 3 win over durvalumab plus chemo.
November 5th, 2026
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
November 9th, 2026
argenx's acquisition of Unnatural Products adds macrocyclic peptides that could yield oral or long-acting treatments for immune-mediated diseases.
November 9th, 2026
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
November 6th, 2026
A real-world study found evolocumab cut fatal or nonfatal heart attack risk 20% vs ezetimibe in adults with ASCVD and prior statin use.
November 6th, 2026
Oxford spinout Alethio Therapeutics closed a $90 million Series A to take ATX-011, a monoclonal antibody against the G6B receptor, into Phase 1/2a studies in essential thrombocythemia. It is also developing a G6B-targeted ADC for myelofibrosis.
来源:BioPharm International · biopharminternational.com







